

Application No.: 10/538,903

Filing Date: June 14, 2005

Page: 2

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently Amended) A cholesterol-reducing and triglyceride-reducing agent comprising water-insoluble carob fiber and at least one n-3 fatty acid, the n-3 fatty acid or the n-3 fatty acids being present at a concentration of at least 15 area % of TFA (area % based on the AOCS Official Method Ce 1b-69; TFA = total fatty acid) said agent providing a greater reduction in cholesterol level than the sum of the effects when the carob fiber or n-3 fatty acid are administered alone.

2. (Currently Amended) The agent as claimed in claim 1, wherein the n-3 fatty acid is a single polyunsaturated fatty acid having a chain length > C12 having at least two double bonds, or its ester, triglyceride, phospholipid, glycolipid, sphingolipid, wax or sterol ester.

3. (Previously Presented) The agent as claimed in claim 1, wherein the n-3 fatty acid is selected from one or more of the following substances: all-cis-9,12,15-octadecatrienoic acid (ALA), all-cis-6,9,12,15-octadecatetraenoic acid, all-cis-11,14,17-eicosatrienoic acid, all-cis-8,11,14,17-eicosatetraenoic acid, all-cis-5,8,11,14,17-eicosapentaenoic acid (EPA), all-cis-13,16,19-docosatrienoic acid, all-cis-7,10,13,16,19-docosapentaenoic acid (DPA) and all-cis-4,7,10,13,16, 19-docosahexaenoic acid (DHA).

4. (Currently Amended) The agent as claimed in claim [[3]] 2, wherein the n-3 fatty acid is all-cis-4,7,10,13,16,19-docosahexaenoic acid (DHA).

5. (Previously Presented) A cholesterol-reducing combination preparation comprising water-insoluble carob fiber and at least one n-3 fatty acid in separate administration forms, the n-

Application No.: 10/538,903

Filing Date: June 14, 2005

Page: 3

3 fatty acid or the n-3 fatty acids being present at a concentration of at least 15 area % of TFA (area % based on the AOCS official method Ce 1b-69; TFA = total fatty acid).

6. (Previously Presented) A method for producing an agent as claimed in claim 1, which comprises mixing at least one carob product and at least one cholesterol-reducing active compound with one another.

7. (Previously Presented) A drug comprising an agent as claimed in claim 1.

8. (Previously Presented) A drug as claimed in claim 7, wherein said drug is a cholesterol-reducing drug.

9. (Previously Presented) A drug as claimed in claim 7 wherein said drug is a hypercholesterolemia, hyperlipidemia or arteriosclerosis drug.

10. (Currently Amended) A drug as claimed in claim 7 wherein said drug ~~positively~~ positively shifts the HDL/LDL ratio.

11. (Currently Amended) An agent as claimed in claim 1, wherein said agent is administered along with an additional supply with of n-3 fatty acids.

12. (New) An agent as claimed in claim 1, wherein said water-insoluble carob fiber is administered in a daily dose ranging from 1 to 15 g.

13. (New) An agent as claimed in claim 1, wherein said n-3 fatty acid is derived from vegetable oil or oils from microorganisms.

14. (New) A cholesterol-reducing agent comprising water-insoluble carob fiber and at least one n-3 fatty acid, the n-3 fatty acid or the n-3 fatty acids being present at a concentration of

Application No.: 10/538,903

Filing Date: June 14, 2005

Page: 4

at least 15 area % of TFA (area % based on the AOCS Official Method Ce 1b-69; TFA = total fatty acid), said n-3 fatty acid consisting of one or more of:

all-cis-9,12,15-octadecatrienoic acid (ALA), all-cis-6,9,12,15-octadecatetraenoic acid, all-cis-11,14,17-eicosatrienoic acid, all-cis-13,16,19-docosatrienoic acid, all-cis-7,10,13,16,19-docosapentaenoic acid (DPA) and all-cis-4,7,10,13,16, 19-docosahexaenoic acid (DHA),

wherein said agent provides a greater reduction in cholesterol level than the sum of the effects when the carob fiber or the n-3 fatty acid are administered alone.

15. (New) An agent as claimed in claim 1, wherein said n-3 fatty acid is administered in a daily dose ranging from 50 mg to 600 mg.